Compare Arko Corp. (ARKO) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arko Corp. vs BridgeBio Pharma Inc — how do they compare? Arko Corp. trades at $4.37 (market cap $527.27M), while BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B). The key difference: BridgeBio Pharma Inc is far larger — about 31.5× Arko Corp.'s market cap, and Arko Corp. pays a 2.55% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| ARKO | BBIO | |
|---|---|---|
Market Cap | $527.27M | $16.61B |
Sector | Consumer Cyclical | Health |
52-Week High | $8.64 | $90.17 |
52-Week Low | $3.82 | $47.29 |
Enterprise Value | $2.71B | $18.16B |
Dividend Yield | 2.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKO Corp. (NASDAQ: ARKO) trades at $5.66, down 22.36% following weak Q2 2026 earnings that missed expectations. The stock shows bearish technical signals with oversold RSI readings near support at $5. Despite revenue declining to $7.64B in 2025, the company maintains positive cash flow and recently paid a $0.03 dividend. Analyst consensus remains cautious with 100% hold ratings amid concerns about consumer spending pressures.
The outlook remains challenging with declining revenues and thin profit margins (0.38% net margin), though management maintains 2026 EBITDA guidance. Key risks include competitive pressure in convenience retail and sensitivity to fuel price volatility. The current valuation at 0.08 P/S ratio may attract value investors if operational improvements materialize.
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arko Corp.
ARKO Corp operates as a holding company. The company, through its subsidiaries, owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in three segments: Retail, Wholesale, and GPM Petroleum. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
Read more on ARKO →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
